Literature DB >> 26077993

Prostate cancer: Docetaxel in high-risk disease.

Rebecca Kelsey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26077993     DOI： 10.1038/nrurol.2015.146

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Authors:  Karim Fizazi; Laura Faivre; François Lesaunier; Remy Delva; Gwenaëlle Gravis; Frédéric Rolland; Frank Priou; Jean-Marc Ferrero; Nadine Houede; Loïc Mourey; Christine Theodore; Ivan Krakowski; Jean-François Berdah; Marjorie Baciuchka; Brigitte Laguerre; Aude Fléchon; Alain Ravaud; Isabelle Cojean-Zelek; Stéphane Oudard; Jean-Luc Labourey; Paule Chinet-Charrot; Eric Legouffe; Jean-Léon Lagrange; Claude Linassier; Gaël Deplanque; Philippe Beuzeboc; Jean-Louis Davin; Anne-Laure Martin; Muriel Habibian; Agnès Laplanche; Stéphane Culine
Journal:  Lancet Oncol       Date:  2015-05-28       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.